J. French

Highlights From the Annual Meeting of the American Epilepsy Society 2022
20231 citationsauthor #30
Impact of genetic polymorphisms on the risk of epilepsy amongst patients with acute brain injury: A systematic review
20239 citationsauthor #8
Time‐to‐event clinical trial designs: Existing evidence and remaining concerns
202313 citationsauthor #8
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy
20235 citationsauthor #2
Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
202321 citationsauthor #15
Appropriate selection of participants for clinical trials in epilepsy.
20237 citationsauthor #1
Increasing challenges to trial recruitment and conduct over time
202316 citationsauthor #8
Treatment Outcomes During Brivaracetam Treatment by Seizure Freedom Status at Baseline: Post hoc Analysis of a Real-world, US Study (P14-1.001)
20230 citationsauthor #2
Impact of Seizures While Driving Prior to Diagnosis in People With Focal Epilepsy
20238 citationsauthor #3
EEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper.
20229 citationsauthor #7
ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions
2022343 citationsauthor #2
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy.
20226 citationsauthor #2
What is a clinical practice guideline? A roadmap to their development. Special report from the Guidelines Task Force of the International League Against Epilepsy
202213 citationsauthor #5
Proposal for an updated seizure classification framework in clinical trials
202220 citationsauthor #8
Long‐term open‐label perampanel: Generalized tonic–clonic seizures in idiopathic generalized epilepsy
20229 citationsauthor #1
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions
2022213 citationsauthor #6
Visually sensitive seizures: An updated review by the Epilepsy Foundation
202291 citationsauthor #4
International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions
2022216 citationsauthor #10
A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination
202221 citationsauthor #1
Time to exceed pre‐randomization monthly seizure count for perampanel in participants with primary generalized tonic–clonic seizures: A potential clinical end point
20229 citationsauthor #7
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy
202223 citationsauthor #3
Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
20226 citationsauthor #1
FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force
202157 citationsauthor #1
Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary
202158 citationsauthor #5
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
202146 citationsauthor #8
Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study
202155 citationsauthor #1
Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy
202112 citationsauthor #1
Antiepileptogenesis and disease modification: Clinical and regulatory issues
202132 citationsauthor #1
Neonatal Outcomes in the MONEAD Study of Pregnant Women with Epilepsy
202114 citationsauthor #13
Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
20213 citationsauthor #4
FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force
202120 citationsauthor #1
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study.
202159 citationsauthor #16
Use of an electronic seizure diary in a randomized, controlled trial of natalizumab in adult participants with drug-resistant focal epilepsy.
20218 citationsauthor #4
Adjunctive everolimus therapy for tuberous sclerosis complex‐associated refractory seizures: Results from the postextension phase of EXIST‐3
202131 citationsauthor #13
Proceedings of the 2020 Epilepsy Foundation Pipeline Conference: Emerging Drugs and Devices.
20212 citationsauthor #5
Have new antiseizure medications improved clinical care over the past 30 years?
20202 citationsauthor #1
Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines
202040 citationsauthor #1
Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy.
202070 citationsauthor #2
The Impact of Clinical Seizure Characteristics on Recognition and Treatment of New‐onset Focal Epilepsy in Emergency Departments
202018 citationsauthor #6
Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study
202048 citationsauthor #9
Do You Believe in Magic (Bullets)?
20201 citationsauthor #1
Proceedings of the 15th Antiepileptic Drug and Device Trials Meeting: State of the Science.
20206 citationsauthor #2
Author response: Keeping people with epilepsy safe during the Covid-19 pandemic
20200 citationsauthor #1
Suicidality of Newer Antiseizure Medications: A Meta-Analysis
20200 citationsauthor #3
Neurologic Manifestations of Systemic Disease: Seizure
20200 citationsauthor #3
Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures
20201 citationsauthor #7
Epilepsy: key experimental therapeutics in early clinical development
202038 citationsauthor #2
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
2020193 citationsauthor #2
Cenobamate for focal seizures — a game changer?
202034 citationsauthor #1
Focal nonmotor versus motor seizures: The impact on diagnostic delay in focal epilepsy
202050 citationsauthor #13
Keeping people with epilepsy safe during the COVID-19 pandemic
2020131 citationsauthor #1
2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction
201919 citationsauthor #4
Classification as autonomic versus sensory seizures
20193 citationsauthor #4
Photosensitive epilepsy
201920 citationsauthor #17
Migraine comorbidity and cognitive performance in patients with focal epilepsy.
201911 citationsauthor #2
A TWO-PART
20195 citationsauthor #1
Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy
201941 citationsauthor #12
Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals
2019251 citationsauthor #186
Collaboration of Care for Women with Epilepsy in their Reproductive Years
20193 citationsauthor #2
Investigation of patient and observer agreement on description of seizures at initial clinical visit
201916 citationsauthor #7
Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)
201946 citationsauthor #6
Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants
201946 citationsauthor #1
Symptoms and Impacts in Epilepsy: Findings from Qualitative Patient Interviews (P1.5-009)
20191 citationsauthor #1
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
2019163 citationsauthor #2
Is seizure frequency variance a predictable quantity?
201843 citationsauthor #4
Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
201852 citationsauthor #13
Reply to Holloway
20180 citationsauthor #1
Common data elements (CDEs) for preclinical epilepsy research: Introduction to CDEs and description of core CDEs. A TASK3 report of the ILAE/AES joint translational task force
201831 citationsauthor #3
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
2018107 citationsauthor #15
Extrapolation of Adjunctive Efficacy and Safety Data from Phase III Partial Epilepsy Trials to Evaluate Perampanel as Monotherapy (P1.259)
20180 citationsauthor #2
Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age
201834 citationsauthor #3
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
201879 citationsauthor #15
Preclinical common data elements (CDEs) for epilepsy: A joint ILAE/AES and NINDS translational initiative
201818 citationsauthor #3
Cenobamate (YKP3089) in Photosensitive Patients: Proof of Principle (P5.279)
20180 citationsauthor #5
Reply to Dr. Wilner
20180 citationsauthor #1
Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
201891 citationsauthor #14
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
2018105 citationsauthor #15
Maintaining Seizure Freedom during Pregnancy and Postpartum: Findings from the MONEAD Study (S11.001)
20180 citationsauthor #2
Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy
201866 citationsauthor #2
Time to Pre-randomization Monthly Seizure Count for Perampanel in Patients with Primary Generalized Tonic-Clonic (PGTC) Seizures: A Potential New Clinical Endpoint (P1.270)
20180 citationsauthor #1
Operationale Klassifikation der Anfallsformen durch die Internationale Liga gegen Epilepsie: Positionspapier der ILAE-Klassifikations- und Terminologiekommission
201825 citationsauthor #3
Long-term safety and efficacy outcomes of adjunctive perampanel: an open-label extension (OLEx) of a Phase III study in patients with drug-resistant primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) (P5.233)
20175 citationsauthor #2
Common data elements for preclinical epilepsy research: Standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE
201731 citationsauthor #2
Treatment issues for children with epilepsy transitioning to adult care.
201742 citationsauthor #7
Inhaled Alprazolam, a Potential Rescue Medication, Works Rapidly in Patients with Photosensitive Epilepsy (P6.236)
20172 citationsauthor #1
Improving clinical trial efficiency: Is technology the answer?
20175 citationsauthor #1
Reducing placebo exposure in trials
201710 citationsauthor #12
Response to the numbering of seizure types
20172 citationsauthor #4
Instruction manual for the ILAE 2017 operational classification of seizure types
2017923 citationsauthor #4
How long for epilepsy remission in the ILAE definition?
20178 citationsauthor #9
De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies.
2017309 citationsauthor #66
Harmonization in preclinical epilepsy research: A joint AES/ILAE translational initiative
201714 citationsauthor #2
Does accounting for seizure frequency variability increase clinical trial power?
201723 citationsauthor #4
Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology
20172,996 citationsauthor #3
Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy
2017282 citationsauthor #7
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study.
2017209 citationsauthor #51
AED Switching: A Game of Skill or a Game of Chance?
20170 citationsauthor #1
Outcomes in patients with tuberous sclerosis complex-associated treatment-refractory seizures, transitioning from placebo in core phase to everolimus during extension phase of the EXIST-3 trial
20171 citationsauthor #1
Withdrawal of antiepileptic drugs: an individualised approach.
20173 citationsauthor #1
Clinical studies and anti‐inflammatory mechanisms of treatments
201748 citationsauthor #1

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT